GLPBio

Yoda1

Catalog No.: GC18233Purity:>98.00%
COASDSData Sheet
Yoda1 is an effective selective agonist of Piezo1 with an EC50 value of 17.1µM in mice.

Products are for research use only. Not for human use. We do not sell to patients.

Yoda1
Cas No.: 448947-81-7
10mM (in 1mL DMSO)In Stock
$71.00
1
1mgIn Stock
$25.00
1
5mgIn Stock
$65.00
1
10mgIn Stock
$87.00
1
25mgIn Stock
$156.00
1
50mgIn Stock
$252.00
1
Tel: (909) 407-4943 / (909) 689-7124Email: sales@glpbio.com

Citations

13 publicationsPublications from researchers using this product

Description

Yoda1 is an effective selective agonist of Piezo1 with an EC50 value of 17.1µM in mice[1]. Yoda1 acts as a molecular wedge, facilitating the opening of Piezo1 when the membrane is stretched, promoting the force-induced conformational changes, thereby effectively reducing the mechanical activation threshold of the channel[2]. Yoda1 activates the Piezo1 channel, leading to Ca2+ influx and a subsequent increase in intracellular Ca2+ concentration[3]. Yoda1 has been widely used in vaccine research as an adjuvant to enhance T-cell activation[4].

In vitro, Yoda1 (1.5µM) was incubated for 10 minutes, which significantly inhibited EGF-stimulated macropinocytosis in A431 cells and prevented peripheral ruffle formation[5]. Treatment with 10µM Yoda1 for 48 hours induced apoptosis in MDA-MB-231 cells and inhibited cell migration[6]. Pretreatment with 10µM Yoda1 for 20min reduced the expression of Periostin in 3T3 cells and altered the expression pathways related to the fibrosis process[7].

In vivo, Yoda1 administration via intraperitoneal injection at a dose of 5µmol/kg/day for 5 days promoted angiogenesis in the intestinal ischemia/reperfusion injury of mice and alleviated intestinal damage[8]. Intraperitoneal injection of Yoda1 at a dose of 4μg/kg at 1 hour before and 12 hours after lipopolysaccharide (LPS) treatment alleviated LPS-induced cardiac dysfunction and oxidative stress in mice[9].

References:

[1] Syeda R, Xu J, Dubin A E, et al. Chemical activation of the mechanotransduction channel Piezo1[J]. elife, 2015, 4: e07369.

[2] Botello-Smith W M, Jiang W, Zhang H, et al. A mechanism for the activation of the mechanosensitive Piezo1 channel by the small molecule Yoda1[J]. Nature communications, 2019, 10(1): 4503.

[3] Qiao M, Penttinen R, Coli A, et al. Piezo1 Channel Activators Yoda1 and Yoda2 in the Context of Red Blood Cells[J]. Biomolecules, 2025, 15(8): 1110.

[4] Goon S, Shiu Chen Liu C, Ghosh Dastidar U, et al. Exploring the structural attributes of Yoda1 for the development of new-generation Piezo1 agonist Yaddle1 as a vaccine adjuvant targeting optimal T cell activation[J]. Journal of Medicinal Chemistry, 2024, 67(10): 8225-8246.

[5] Kuriyama M, Hirose H, Masuda T, et al. Piezo1 activation using Yoda1 inhibits macropinocytosis in A431 human epidermoid carcinoma cells[J]. Scientific reports, 2022, 12(1): 6322.

[6] Lin C Y, Song X, Ke Y, et al. Yoda1 enhanced low-magnitude high-frequency vibration on osteocytes in regulation of MDA-MB-231 breast cancer cell migration[J]. Cancers, 2022, 14(14): 3395.

[7] Alam P, Stiens S M, Bowles H J, et al. Yoda1 inhibits TGFβ-induced cardiac fibroblast activation via a BRD4-dependent pathway[J]. Cells, 2025, 14(13): 1028.

[8] Wang C, Luo S, Yan Y, et al. Endothelial Piezo1 stimulates angiogenesis to offer protection against intestinal ischemia–reperfusion injury in mice[J]. Molecular Medicine, 2025, 31(1): 147.

[9] Yang Y, Tian Q, Qiu F, et al. Yoda1/Piezo1 alleviates lipopolysaccharide-induced cardiac injury via AMPK-mediated mitophagy[J]. Cardiovascular Toxicology, 2025, 25(10): 1604-1615.

Protocol

Cell experiment [1]:

Cell lines

 MDA-MB-231 cells

Preparation Method

 MDA-MB-231 cells were cultured in MLO-Y4 medium supplemented with 2.5% calf serum, 2.5% fetal bovine serum, and 1% penicillin streptomycin at 37°C in an incubator with 5% CO2. Cells were seeded in a 96-well plate at a density of 1.5×105 cells/well for 24h, with three replicates for each treatment. Cells were treated with different concentrations of Yoda1 (0, 1, 2, 5, and 10μM). After 48h of treatment, the cell viability was determined.

Reaction Conditions

 0, 1, 2, 5, and 10μM; 48h

Applications

 Yoda1 treatment inhibited the cell viability of MDA-MB-231 cells in a dose-dependent manner.
Animal experiment [2]:

Animal models

 Male C57BL/6 J mice

Preparation Method

Male C57BL/6 J mice (8 weeks old) were maintained in a controlled environment at 21±1°C and 60% relative humidity under a 12h light/dark cycle, and were given free access to food and water. Mice were fasted for 12h before surgery, with water provided ad libitum. Following surgical site preparation, the mice were rendered unconscious through inhalation of 2% isoflurane. A 1-2cm incision was made along the abdominal midline, and then the abdominal layers were sequentially separated. The first-order branch of the superior mesenteric artery was isolated using blunt dissection techniques. Mesenteric ischemia was induced by clamping the ileal vessels with a microvascular clamp, and successful induction was verified by observing the resultant pallor of the ileum. After 30min of ischemia, the clamp was taken away, and the abdominal wound was sutured. The mice were euthanized at 48 and 72h post-reperfusion for further analysis. For Yoda1 treatment, a 50mM stock solution was prepared by dissolving Yoda1 in dimethyl sulfoxide (DMSO). For experimental use, the saline was used to dilute the stock solution to achieve a final concentration of 5µmol/kg. Mice were continuously injected with Yoda1 (5µmol/kg/day) intraperitoneally for 5 days one week before surgery.

Dosage form

5µmol/kg/day; 5 days; i.p.

Applications

Yoda1 treatment promoted angiogenesis in the intestinal ischemia/reperfusion injury of mice and alleviated intestinal damage.

References:

[1] Lin C Y, Song X, Ke Y, et al. Yoda1 enhanced low-magnitude high-frequency vibration on osteocytes in regulation of MDA-MB-231 breast cancer cell migration[J]. Cancers, 2022, 14(14): 3395.

[2] Yang Y, Tian Q, Qiu F, et al. Yoda1/Piezo1 alleviates lipopolysaccharide-induced cardiac injury via AMPK-mediated mitophagy[J]. Cardiovascular Toxicology, 2025, 25(10): 1604-1615.

Product Documents

Purity:>98.00%Appearance:A solid
COASDSData Sheet

Biological Data

1 / 3

Chemical Properties

CAS No.
448947-81-7
Chemical Name
2-[5-[[(2,6-dichlorophenyl)methyl]thio]-1,3,4-thiadiazol-2-yl]-pyrazine
SMILES
ClC(C=CC=C1Cl)=C1CSC2=NN=C(C3=CN=CC=N3)S2
Molecular Formula
C13H8Cl2N4S2
Molecular Weight
355.3
Solubility
DMSO：50mg/mL
Storage
Store at -20°C
General tips
Select a suitable solvent according to the product solubility data. Once prepared, aliquot the stock solution to avoid repeated freeze-thaw cycles.
Use stock solutions within 6 months when stored at -80°C or within 1 month when stored at -20°C.
To improve solubility, warm the tube to 37°C and sonicate it for an appropriate period.
Shipping Condition
Evaluation samples are shipped with blue ice. Other available sizes are shipped at room temperature or with blue ice upon request.

CalculatorsMolarity / Dilution / Molecular Weight / Unit Conversion / In Vivo Formulation / Solubility

g/mol

Reviews

Review for Yoda1

Rating: 5
  • 5 Star100%
  • 4 Star0%
  • 3 Star0%
  • 2 Star0%
  • 1 Star0%